Reigetsu Yoshikawa - Concepedia

Author

Reigetsu Yoshikawa

Hyogo Medical University

Also Known As

D Sharma, R YOSHIKAWA, R Yoshikawa, R. Yoshikawa, R., Yoshikawa, REIGETSU YOSHIKAWA, Reigetsu Yoshikawa

Publications

986

Citations

H-Index

Concepts

All Affiliations

Hyogo Medical University Kindai University Eli Lilly (Japan)National Cancer Center Hospital East Kanagawa Prefectural Hospital Organization

About

Reigetsu Yoshikawa is an author at Hyogo Medical University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	250
2	Health Sciences	1	1	11
3	Cell Biology	1	1	194
4	Hepatology	1	1	11
5	Immunology	1	1	11

Reigetsu Yoshikawa

Publications

883

Citations

H-Index

Page 1

	Year	Citations
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Reigetsu Yoshikawa, M. Kusunoki, Hidenori Yanagi, PubMed OncologyMedicineMetronomic TherapyPathologyColorectal Cancer	2001	194
Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis Makoto Gega, Hidenori Yanagi, Reigetsu Yoshikawa, Journal of Clinical Oncology	2005	182
Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy Reigetsu Yoshikawa, Yoshiro Nakano, Lihua Tao, British Journal of Cancer	2008	67
ECA39 is a novel distant metastasis-related biomarker in colorectal cancer Reigetsu Yoshikawa World Journal of Gastroenterology	2006	53
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, JHEP Reports	2020	53
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases Masato Kusunoki, Hidenori Yanagi, Masafumi Noda, Cancer	2000	41
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia Takaki Yoshikawa, Kei Muro, Kohei Shitara, JAMA Network Open	2019	38
Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug Keita Tanaka, Reigetsu Yoshikawa, Hidenori Yanagi, World Journal of Surgical Oncology	2008	37
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Journal of Gastroenterology	2020	32
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Liver International	2020	31

Page 1